Spots Global Cancer Trial Database for disitamab vedotin
Every month we try and update this database with for disitamab vedotin cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| A Study of the Treatment of Disitamab Vedotin in Patients With Locally Advanced or Metastatic Pancreatic Cancer | NCT06233864 | Pancreatic Canc... | Disitamab Vedot... Gemcitabine | 18 Years - | Sun Yat-sen University | |
| Disitamab Vedotin Combined With Radiotherapy for Bladder Preservation | NCT05912205 | Urothelial Carc... | Disitamab Vedot... radiotherapy | 18 Years - | Wuhan Union Hospital, China | |
| Disitamab Vedotin + Pyrotinib Versus THP in the First-line Treatment for HER2+ Advanced Breast Cancer Clinical Trial | NCT06278870 | HER2-positive M... First-line Trea... | disitamab vedot... Pyrotinib trastuzumab Pertuzumab taxane drug | 18 Years - 75 Years | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| RC48-ADC in Breast Cancer | NCT05851677 | Breast Cancer | Disitamab vedot... | - | RenJi Hospital | |
| Disitamab Vedotin Combined With Radiotherapy for Bladder Preservation | NCT05912205 | Urothelial Carc... | Disitamab Vedot... radiotherapy | 18 Years - | Wuhan Union Hospital, China | |
| A Study of Disitamab Vedotin in Previously Treated Solid Tumors That Express HER2 | NCT06003231 | Carcinoma, Squa... Carcinoma, Non-... Ovarian Neoplas... Endometrial Neo... | disitamab vedot... | 18 Years - | Seagen Inc. | |
| Real-world Study of HER2-overexpressed Advanced Solid Tumors After Progression of First-line Standard Therapy | NCT05649163 | HER2 Advanced Gastri... Advanced Gastro... Advanced Solid ... | Disitamab Vedot... | 18 Years - | Peking University | |
| Disitamab Vedotin Combined Therapy for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations | NCT05847764 | Non Small Cell ... ERBB2 Mutation-... RC48 Disitamab Vedot... | RC48+Tislelizum... RC48+Furmonerti... RC48+Furmonerti... | 18 Years - | Sun Yat-sen University | |
| A Study of the Treatment of Disitamab Vedotin in Patients With Locally Advanced or Metastatic Pancreatic Cancer | NCT06233864 | Pancreatic Canc... | Disitamab Vedot... Gemcitabine | 18 Years - | Sun Yat-sen University | |
| Disitamab Vedotin(RC48) Combined With Penpulimab(AK105) for Neoadjuvant Treatment of HER2-low Breast Cancer | NCT05726175 | Breast Cancer | Disitamab Vedot... Penpulimab | 18 Years - 75 Years | West China Hospital | |
| Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma. | NCT06155383 | Gastric Cancer Gastroesophagea... | Capecitabine oxaliplatin Disitamab Vedot... Toripalimab | 18 Years - | RemeGen Co., Ltd. | |
| Perioperative Disitamab Vedotin Plus Toripalimab and XELOX in Gastric or Gastroesophageal Junction Adenocarcinoma. | NCT06155383 | Gastric Cancer Gastroesophagea... | Capecitabine oxaliplatin Disitamab Vedot... Toripalimab | 18 Years - | RemeGen Co., Ltd. | |
| RC48-ADC in HER2-low Advanced Breast Cancer | NCT05831878 | Advanced Breast... | Disitamab vedot... | 18 Years - 70 Years | RenJi Hospital | |
| Disitamab Vedotin Combined With BCG Therapy in HER2-expressing High-risk Non-muscle Invasive Bladder Cancer | NCT06187506 | Non-muscle Inva... HER-2 Protein O... | Disitamab vedot... Bacillus Calmet... | 18 Years - | Fudan University | |
| Study of Disitamab Vedotin With Toripalimab Verus Disitamab Vedotin in Hormone Receptor Positive, HER2-low Locally Advanced or Metastatic Breast Cancer | NCT06105008 | Breast Neoplasm... | Disitamab Vedot... Toripalimab | 18 Years - | RemeGen Co., Ltd. | |
| Real-world Study of HER2-overexpressed Advanced Solid Tumors After Progression of First-line Standard Therapy | NCT05649163 | HER2 Advanced Gastri... Advanced Gastro... Advanced Solid ... | Disitamab Vedot... | 18 Years - | Peking University | |
| Study of Disitamab Vedotin and Anlotinib in Patients With HR-Negative, HER2-Low-Expressing Metastatic Breast Cancer | NCT06000033 | Breast Cancer | Disitamab Vedot... | 18 Years - | Qilu Hospital of Shandong University | |
| RC48 Combined With EGFR or HER2 TKI for Locally Advanced or Metastatic NSCLC Patients With HER2 Alterations | NCT06185400 | Non Small Cell ... ERBB2 Mutation-... ERBB2 Gene Dupl... Disitamab Vedot... | Disitamab Vedot... third-generatio... pyrotinib | 18 Years - | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | |
| Disitamab Vedotin Combined With BCG Therapy in HER2-expressing High-risk Non-muscle Invasive Bladder Cancer | NCT06187506 | Non-muscle Inva... HER-2 Protein O... | Disitamab vedot... Bacillus Calmet... | 18 Years - | Fudan University | |
| Disitamab Vedotin Combined With Tislelizumab in Advanced HER2 Positive Colorectal Cancer | NCT05493683 | Colorectal Neop... | Disitamab vedot... Tislelizumab | 18 Years - | The First Affiliated Hospital with Nanjing Medical University | |
| A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2 | NCT04879329 | Urothelial Carc... | disitamab vedot... pembrolizumab | 18 Years - | Seagen Inc. | |
| RC48-ADC Combined With Radiotherapy in the Treatment of Locally Advanced Solid Tumors With HER2 Expression | NCT05940896 | Solid Tumor | Disitamab vedot... | 18 Years - | RemeGen Co., Ltd. | |
| Posterior-line Treatment With Disitamab Vedotin Plus PD-1 in Advanced HER2-low Expressing Gastric Cancer | NCT06078982 | Gastric Cancer HER2-low-expres... | Disitamab Vedot... Toripalimab | 18 Years - 70 Years | Shanghai East Hospital | |
| A Study of Disitamab Vedotin Alone or With Other Anticancer Drugs in Solid Tumors | NCT06157892 | Breast Neoplasm... Gastroesophagea... HER2 Low Breast... HER2 Positive B... Stomach Neoplas... Triple Negative... | disitamab vedot... tucatinib | 18 Years - | Seagen Inc. | |
| Study of Disitamab Vedotin and Anlotinib in Patients With HR-Negative, HER2-Low-Expressing Metastatic Breast Cancer | NCT06000033 | Breast Cancer | Disitamab Vedot... | 18 Years - | Qilu Hospital of Shandong University | |
| First-line Treatment With RC48 Plus Tislelizumab and S-1(RCTS) in Advanced Gastric Cancer | NCT05586061 | HER2-positive G... | Disitamab vedot... Tislelizumab S1 | 18 Years - 75 Years | Qilu Hospital of Shandong University | |
| RC48-ADC Combined With Radiotherapy in the Treatment of Locally Advanced Solid Tumors With HER2 Expression | NCT05940896 | Solid Tumor | Disitamab vedot... | 18 Years - | RemeGen Co., Ltd. | |
| Disitamab Vedotin(RC48) Combined With Penpulimab(AK105) for Neoadjuvant Treatment of HER2-low Breast Cancer | NCT05726175 | Breast Cancer | Disitamab Vedot... Penpulimab | 18 Years - 75 Years | West China Hospital | |
| A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2 | NCT04879329 | Urothelial Carc... | disitamab vedot... pembrolizumab | 18 Years - | Seagen Inc. | |
| Pembrolizumab and Disitamab Vedotin in HER2-expressing Metastatic Colorectal Cancer | NCT05333809 | Colorectal Neop... | Pembrolizumab Disitamab vedot... | 18 Years - | Shanghai Zhongshan Hospital |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
